The Taiwan Society of Cardiology (TSOC) was founded in 1960, and has more than 2,000 cardiologists among its active membership. Acta Cardiologica Sinica, the official journal of TSOC, had been published quarterly since 1985, and has been bimonthly since 2013. Acta Cardiologica Sinica was listed in SCIE in 2007, and had a journal impact factor (JIF) of 0.253 by 2009. The most recent JIF is 1.900 in 2022.
Acta Cardiologica Sinica welcomes all papers in the fields related to cardiovascular medicine, including basic research, vascular biology, cardiovascular pharmacology, general cardiology, epidemiology, coronary artery disease, peripheral artery disease, interventional cardiology, critical care medicine, arrhythmia and electrophysiology including device therapy, preventive cardiology, atherosclerosis, hypertension, cardiomyopathy, heart failure, cardio-oncology, valvular and structure cardiac diseases, pulmonary hypertension, pediatric cardiology, cardiovascular surgery, and so on. We encourage innovative fields such as big data, artificial intelligence, digital health, and multidisciplinary. To further enhance the impact of Acta Cardiological Sinica to the global cardiology society, we welcome the submission of clinical trials, protocols of registered trials, guidelines or consensus statements from national or regional societies, and reviews of novel topics.
Currently, we received papers from more than 30 countries and regions of the world. Currently, 35% of the papers were submitted from Turkey, 26% from China, 24% from Taiwan, and 15% from the rest of the world.
We dedicate to speed up the editorial process and maintain the high-quality of articles published. Our goal is to make Acta Cardiologica Sinica the top cardiology journal in Asia.